Log In
Print
BCIQ
Print
Print this Print this
 

Feraccru, ferric maltol (ST10)

  Manage Alerts
Collapse Summary General Information
Company Shield Therapeutics AG
DescriptionOral ferric iron non-covalently bound to 3 maltol molecules
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationAnemia
Indication DetailsTreat iron deficiency anemia associated with chronic kidney disease (CKD); Treat iron deficiency anemia associated with Crohn's disease; Treat iron deficiency anemia associated with inflammatory bowel disease (IBD); Treat iron deficiency anemia associated with ulcerative colitis (UC); Treat iron deficiency anemia in patients who have failed or otherwise cannot take oral iron therapy; Treat iron deficiency anemia in pre-dialysis patients with chronic kidney disease (CKD)
Regulatory Designation

Partner

AOP Orphan Pharmaceuticals AG


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$1.7M

$2.4M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today